Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7252794 | 0.81 | CA1 (0.39) | PARP1FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL7103316 | 0.81 | MAPT (0.39) | KDM4EGAAFGFR1FGFR2FGFR4 | |
| SCHEMBL7098113 | 0.81 | SMN1; SMN2 (0.39) | KDM4EGAAFGFR1FGFR2FGFR4 | |
| SCHEMBL3747951 | 0.79 | BACE1 (0.43) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL22075719 | 0.78 | MEN1 (0.41) | KDM4EFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL7104932 | 0.77 | KDM4E (0.32) | KDM4EGAAFGFR1FGFR2FGFR4 | |
| SCHEMBL7172007 | 0.76 | KDM4E (0.32) | KDM4EFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL7098749 | 0.75 | LMNA (0.31) | KDM4EGAAFGFR1FGFR2FGFR4 | |
| SCHEMBL7103565 | 0.72 | FGFR1 (0.31) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL7100200 | 0.72 | FGFR1 (0.33) | FGFR1FGFR2FGFR4FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
| EP-1259491-A1 | 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS | Abbott Laboratories (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060802-A1 | 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES, AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS | ABBOTT LABORATORIES (US) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | PARP1 3891/4885KDM4E 823/4885GAA 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.